The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
=== Women's health === The Panorama NIPT is the only single-nucleotide polymorphism (SNP)-based NIPT. The test analyzes fetal DNA found in the mother's blood to reveal a baby's risk for genetic disorders such as Down syndrome (trisomy 21) and Edwards syndrome (trisomy 18) as early as nine weeks. Panorama also tests for unique microdeletions and is the only test that can detect zygosity and fetal sex in twins. Natera also offers Horizon, a carrier-screening test that uses next-generation sequencing to provide carrier status for up to 274 genetic conditions. Additionally, Natera offers the Anora products of conception (POC) miscarriage test, the Spectrum preimplantation genetic screening and diagnosis test, and the Vistara single-gene prenatal screening test. In 2020, Natera launched Empower, a hereditary cancer test that screens for up to 53 genes associated with increased risk for common hereditary cancers.
The Bergmann azlactone peptide synthesis is a classic organic synthesis process for the preparation of dipeptides. In the presence of a base, peptides are formed by aminolysis of N-carboxyanhydrides of amino acids with amino acid esters (1).
Alcohol: It has been reported that combined use of alcohol and kava extract can have additive sedative effects. Kava has been shown to create additive cognitive impairments when taken with alcohol, compared to taking placebo and alcohol alone. Anxiolytics (CNS depressants such as benzodiazepines and barbiturates): Kava may have potential additive CNS depressant effects (such as sedation and anxiolytic effects) with benzodiazepines and barbiturates. Kava taken in combination with alprazolam can cause a semicomatose state in humans. Dopamine agonist such as levodopa: One of levodopa's chronic side effects in Parkinson's patients is the "on-off phenomenon" of motor fluctuations - periods of oscillations between "on", where the patient experiences symptomatic relief, and "off", where the therapeutic effect wears off early. When levodopa and kava are taken together, it has been shown that there is an increased frequency of this "on-off phenomenon".
Peukert argued there was a disconnect between the popular image today of the Nazi era as a time of unparalleled horror vs. the way in which most ordinary Germans remembered it as a time of benign "normality", and that studying Alltagsgeschichte would explore what the Third Reich was actually like in "everyday life". In the early 1980s, Alltagsgeschichte exploded in popularity in West Germany with numerous work groups being set, usually by left-wing groups, to explore the history of their home towns in the Nazi era. The study of Alltagsgeschichte was greatly influenced by the History Workshop movement in Britain set up by the Marxist historian E.P. Thompson and like the British Workshop groups, many involved in the Alltagsgeschichte study groups were not historians with a disproportional number of the volunteers being high-school students. The American historian Mary Nolan wrote with some envy about the way in which thousands of German high school students became involved in the Alltagsgeschichte study groups, observing that it was simply inconceivable that thousands of American high school students would join study groups to research the histories of their home towns in the 1930s-1940s as most Americans have no interest in history. In 1984, Peukert was awarded the annual culture prize given by the city of Essen for his work with a history workshop group in Essen.
The diagnosis of cirrhosis in an individual is based on multiple factors. Cirrhosis may be suspected from laboratory findings, physical exam, and the person's medical history. Imaging is generally obtained to evaluate the liver. A liver biopsy will confirm the diagnosis; however, is generally not required.
Sources: en.wikipedia.org
=== For Alzheimer's disease === Several companies are in the early stages of development and testing of this potential class of treatment. In March 2008 phase I results were reported for CoMentis Inc's candidate CTS-21166. In April 2012 Merck & Co., Inc reported phase I results for its candidate verubecestat (MK-8931). Merck began a Phase II/III trial of MK-8931 in December, 2012 estimated to be completed in July 2019. In February 2017, Merck halted its late-stage trial of verubecestat for mild to moderate Alzheimer's disease after it was reported as having "virtually no chance" of working according to an independent panel of experts. This came just three months after Eli Lilly & Co. announced its own setback with solanezumab. In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop lanabecestat (AZD3293). A pivotal Phase II/III clinical trial of lanabecestat started in late 2014, but was halted in 2018 before its planned conclusion due to poor results. Another BACE1 inhibitor that has reached phase II trials is the Eli Lilly's inhibitor LY2886721. The data on phase I trial were first presented at the Alzheimer's Association International conference in 2012. Daily dosing during 2 weeks, reduced BACE1 activity by 50–75% and CSF Aβ42 by 72% (Willis et al., 2012; Bowman Rogers and Strobel, 2013). Recently, Lilly reported that the phase II trial of LY2886721 was terminated due to liver abnormalities that were found in 4 out of 45 patients (Rogers, 2013).
==== Syria ==== In 2024 it was acknowledged that five SAS members were under investigation by the Defence Serious Crime Unit on suspicion of committing war crimes in Syria, though details were not disclosed by the Ministry of Defence.
After 1869, Dmitri Mendeleev proposed his periodic table placing lithium at the top of a group with sodium, potassium, rubidium, caesium, and thallium. Two years later, Mendeleev revised his table, placing hydrogen in group 1 above lithium, and also moving thallium to the boron group. In this 1871 version, copper, silver, and gold were placed twice, once as part of group IB, and once as part of a "group VIII" encompassing today's groups 8 to 11. After the introduction of the 18-column table, the group IB elements were moved to their current position in the d-block, while alkali metals were left in group IA. Later the group's name was changed to group 1 in 1988. The trivial name "alkali metals" comes from the fact that the hydroxides of the group 1 elements are all strong alkalis when dissolved in water. There were at least four erroneous and incomplete discoveries before Marguerite Perey of the Curie Institute in Paris, France discovered francium in 1939 by purifying a sample of actinium-227, which had been reported to have a decay energy of 220 keV. However, Perey noticed decay particles with an energy level below 80 keV. Perey thought this decay activity might have been caused by a previously unidentified decay product, one that was separated during purification, but emerged again out of the pure actinium-227. Various tests eliminated the possibility of the unknown element being thorium, radium, lead, bismuth, or thallium.
Absenta ("absinthe" in Spanish) is sometimes associated with a regional style that often differed slightly from its French cousin. Traditional absentas may taste slightly different due to their use of Alicante anise, and often exhibit a characteristic citrus flavour. Hausgemacht (German for home-made, often abbreviated as HG) refers to clandestine absinthe (not to be confused with the Swiss La Clandestine brand) that is home-distilled by hobbyists. It should not be confused with absinthe kits. Hausgemacht absinthe is produced in tiny quantities for personal use and not for the commercial market. Clandestine production increased after absinthe was banned, when small producers went underground, most notably in Switzerland. Although the ban has been lifted in Switzerland, some clandestine distillers have not legitimised their production. Authorities believe that high taxes on alcohol and the mystique of being underground are likely reasons.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.